Letrozol 2.5mg/tab 60 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Confirm long-ester clearance before starting letrozole — for compounds such as testosterone undecanoate or nandrolone decanoate, allow at least 14–21 days post-last-injection before initiating.
2. Where HCG is part of the protocol, run HCG concurrent with or immediately prior to the letrozole phase to prime Leydig cell responsiveness before gonadotropin secretion resumes naturally.
3. Begin at 2.5 mg daily for the first two weeks; use the 2.5 mg tablet as a single unit — do not split during the initial high-suppression window.
4. From week three onward, step down to 2.5 mg every other day; use estradiol bloodwork (LCMS-verified E2 assay, not immunoassay) to confirm the dose is appropriate rather than over-suppressing.
5. During weeks five and six, split the 2.5 mg tablet to achieve a 1.25 mg dose on alternate days; the tablet's compressed uniformity makes this reduction reliable.
6. Discontinue letrozole and transition to a SERM (e.g. tamoxifen or clomiphene) once estradiol has stabilised in the low-normal physiological range; continue SERM for a further four to six weeks as the final recovery phase.

Warnings

Frequently asked questions

What makes PCT after a heavy multi-compound AAS cycle harder than other recovery scenarios?

Heavy multi-compound cycles produce deeper and more prolonged HPTA suppression than single-compound or lower-dose protocols. Long-ester androgens extend the clearance window, meaning exogenous hormone levels remain active longer, delaying the recovery start point. The resulting gonadotropin deficit is correspondingly severe, and the aromatase rebound upon drug clearance is typically more pronounced, requiring a structured, extended aromatase-inhibitor phase before SERM transition is appropriate.

Should HCG be used before starting letrozole in a heavy-cycle recovery protocol?

Yes — for heavy cycles, HCG is widely used before or concurrent with the letrozole phase to restore Leydig cell sensitivity prior to relying on endogenous LH. Prolonged suppression can leave Leydig cells unresponsive to gonadotropin signalling; HCG provides direct LH-receptor stimulation to reactivate testicular steroidogenic capacity. Letrozole then manages estradiol during and after this priming phase, creating conditions under which subsequent SERM therapy can drive meaningful LH and FSH output.

How long does full HPTA restoration typically take following a long-duration heavy cycle?

Full HPTA restoration after a prolonged heavy cycle can take three to six months in total, with individual variation depending on cycle length, compounds used, and pre-cycle baseline testosterone. The aromatase-inhibitor phase typically spans four to six weeks, followed by a SERM phase of similar length, and then a monitoring period to confirm sustained endogenous testosterone production. Bloodwork at the conclusion of the SERM phase — assessing LH, FSH, and total testosterone — is the only reliable indicator of genuine recovery.

Why is the 2.5 mg per tablet format the most practical choice for tapering during heavy-cycle PCT?

The 2.5 mg tablet is the lowest single-unit increment in this product group, which means dose reductions can be achieved in the smallest possible steps without compounding errors. Splitting a 2.5 mg tablet in half yields a 1.25 mg dose — an increment that would be impractical to achieve from a higher-strength tablet with acceptable accuracy. For heavy-cycle recovery, where the taper spans several weeks and dose precision matters, the 2.5 mg unit provides more protocol flexibility than any larger format.

How does Sterling Knight's Batch Tested standard apply to this letrozole product specifically?

Batch Tested status means each production lot of Sterling Knight Letrozole 2.5 mg/tab is subjected to HPLC content-uniformity analysis against a certified letrozole reference standard and LAL endotoxin testing before release. The resulting data is compiled into a traceable certificate of analysis specific to that lot number. No batch enters distribution until both analytical criteria are satisfied and documented — providing independent, method-confirmed assurance of potency rather than relying on supplier certificates alone. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals' tablet presentation strategy for its Letrozole 2.5 mg/tab product is anchored in a specific clinical-use observation: heavy-cycle PCT protocols operate across multiple sequential dose levels — 2.5 mg daily, every other day, and split half-tablet increments — and the physical integrity of each tablet at the point of splitting determines whether those reductions are pharmacologically meaningful or approximate. To ensure that a tablet halved on day thirty delivers the same 1.25 mg fraction as a tablet halved on day one, Sterling Knight applies a controlled wet-granulation and compression sequence specifically validated for letrozole API distribution across the full tablet matrix. Each blister is sealed under inert-atmosphere packaging conditions to protect against humidity-induced API degradation across the 60-tablet supply window typical of heavy-cycle recovery timelines. Batch Tested release criteria require that HPLC content-uniformity data and LAL endotoxin results are affixed to a fully traceable certificate of analysis for every production lot — a standard that applies uniformly across Sterling Knight's oral tablet range regardless of whether the per-tablet API load is measured in milligrams or micrograms.